A Repeated Dose-finding Study of Sarilumab in Children and Adolescents With Systemic Juvenile Idiopathic Arthritis (SKYPS)
Investigating Treatment for Systemic Juvenile Idiopathic Arthritis in Children and Adolescents
Study Overview
Primary Objective:
To describe the pharmacokinetic (PK) profile of sarilumab in patients aged 1-17 years with Systemic Juvenile Idiopathic Arthritis (sJIA) in order to identify the dose and regimen for adequate treatment of this population.
Secondary Objective:
To describe the pharmacodynamics (PD) profile, the efficacy, and the long term safety of sarilumab in patients with sJIA.
Study Details
The total study duration per patient will be 166 weeks that will consist of a 4- week screening, a 12-week core treatment phase, a 144-week extension phase, and a 6-week post-treatment follow-up.
Eligibility Criteria
You may be eligible for this study if you meet the following criteria:
- Conditions: Juvenile Idiopathic Arthritis
-
Age: 1 year - 17 years
-
Gender: All
Inclusion criteria :
- Male and female patients aged ≥1 and ≤17 years (or country specified age requirement, 12-17 years for Russia) at the time of the screening visit.
- Diagnosis of systemic JIA subtype according to the International Associations
against Rheumatism (ILAR) 2001 Juvenile Idiopathic Arthritis (JIA) Classification
Criteria with the following features:
- 5 active joints at screening or
- 2 active joints at screening with systemic JIA fever >37.5 0C in the 3 days preceding baseline or for at least 3 out of any 7 consecutive days during screening despite glucocorticoids at a dose stable for at least 3 days.
- Patient with an inadequate response to current treatment and considered as a
candidate for a biologic disease modifying anti rheumatic drug (DMARD) as per investigator's judgment.
Exclusion criteria:
- Body weight <10 kg or >60 kg for patients enrolled in the ascending dose cohorts, then body weight <10 kg for patients subsequently enrolled at the selected dose.
- Uncontrolled severe systemic symptoms and/or Macrophage Activation Syndrome (MAS) within 6 months prior to screening.
- History of or ongoing interstitial lung disease, pulmonary hypertension, pulmonary alveolar proteinosis.
- If nonsteroidal anti-inflammatory drugs (NSAIDs) (including cyclo oxygenase-2 inhibitors [COX-2]) taken, dose stable for less than 2 weeks prior to the baseline visit and/or dosing prescribed outside of approved label.
- If non-biologic DMARD taken, dose stable for less than 6 weeks prior to the baseline visit or at a dose exceeding the recommended dose as per local labeling.
- If oral glucocorticoid taken, dose exceeding equivalent prednisone dose 1 mg/kg/day (or 60 mg/day) within 3 days prior to baseline.
- Use of parenteral or intra-articular glucocorticoid injection within 4 weeks prior to baseline.
- Prior treatment with anti-interleukin 6 (IL-6) or IL-6 receptor (IL-6R) antagonist therapies, including but not limited to tocilizumab or sarilumab.
- Treatment with any biologic treatment for sJIA within 5 half-lives prior to the first dose of sarilumab (the required off treatment periods and procedures may vary according to local requirements).
- Treatment with a Janus kinase inhibitor within 4 weeks prior to the first dose of sarilumab; and treatment with growth hormone within 4 weeks prior to the first dose of sarilumab (the required off treatment periods and procedures may vary according to local requirements).
- Treatment with any investigational biologic or non-biologic product within 8 weeks or 5 half-lives prior to baseline, whichever is longer.
- Exclusion related to tuberculosis.
- Exclusion criteria related to past or current infection other than tuberculosis.
- Any live, attenuated vaccine within 4 weeks prior to the baseline visit, such as varicella-zoster, oral polio, rubella vaccines. Killed or inactive vaccine may be permitted based on the Investigator's judgment.
- Exclusion related to history of a systemic hypersensitivity reaction to any biologic drug and known hypersensitivity to any constituent of the product.
- Laboratory abnormalities at the screening visit (identified by the central laboratory).
- Severe cardiac disease due to sJIA.
- Pregnant or breast-feeding female adolescent patients.
The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.
This study investigates the treatment of Systemic Juvenile Idiopathic Arthritis (sJIA) in children and adolescents aged 1 to 17 years. sJIA is a type of arthritis that causes joint pain and swelling, along with fever and rash. The study aims to understand how the investigational medication is processed in the body, known as pharmacokinetics, to determine the appropriate dose and schedule for this age group.
Participants in the study will undergo various procedures to assess the effectiveness and safety of the investigational medication over a long period. The study will include regular monitoring of health and symptoms to ensure the treatment is working as intended and to check for any side effects. The procedures will also help in understanding the medication's impact on the body over time.
- Who can participate: Children and adolescents aged 1 to 17 years with Systemic Juvenile Idiopathic Arthritis (sJIA) may participate. Participants must have a certain number of active joints or fever related to sJIA and must not respond adequately to current treatments. Specific weight and medication history criteria also apply.
- Study details: Participants will receive an investigational medication to study its effects on sJIA. Some participants may receive a placebo, which is an inactive substance that looks like the investigational medication but does not contain any medicine. Regular health assessments will be conducted to monitor the treatment's effects.
- Study Timelines: The study will last 166 weeks.
Find a Study Location to Connect
,
You have contacted , on
Your message has been sent to the study team at ,
What happens next?
- You can expect the study team to contact you via email or phone in the next few days.
- Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.
You are contacting
Primary Contact